On July 15, Alibaba Health rose 3.03% in regular trading, trading at 3.39 HKD/share, with turnover of HKD 206 million. The stock rebounded after two consecutive days of significant declines that had driven it near a low of 3.16 HKD, approaching UBS's sell target price of 3.1 HKD before attracting buying support.

The broader Internet and direct marketing retail sector rallied today, with peers JD Health up 2.16%, Alibaba up 2.8%, and Meituan up 5.93%, providing a clear lift through sector linkage. The rebound follows a period of heavy selling pressure that weighed on the pharma e-commerce space, during which southbound capital had cumulatively reduced holdings by over 128 million shares over the prior 20 trading days.

On the ratings front, Bank of America Securities and Jefferies both maintain Buy ratings on Alibaba Health with target prices of 5.1 HKD and 5.3 HKD respectively, significantly above the current trading level, while UBS holds a contrarian Sell rating at 3.1 HKD. This bull-bear divergence has prompted selective bargain-hunting by some funds near technical support levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)